BioCloner technology is a groundbreaking advancement in the field of 3D bioprinting, with the real potential to transform modern medicine. Developed by BioCloner Health, the system is attracting increasing interest—not only in Poland and Europe but also internationally. In response to this growing attention, company representatives Maciej Tabiszewski and Maciej Gołaszewski traveled to the United States to present the technology and establish key connections within the scientific and business communities.
During their visit, they held a series of meetings with leading professors, researchers, and investors. They also visited renowned research institutions such as Stanford University, the Poland in Silicon Valley Center, and cutting-edge technology labs including MBC BioLabs and the Skylar-Scott Lab. This trip marks a significant milestone on BioCloner Health’s path to entering the global market and confirms the growing interest in solutions that could redefine the future of medicine.
The journey began with a visit to PolSV—an organization that fosters collaboration between Polish scientific, academic, and startup communities and Silicon Valley. Its mission is to support the scientific, technological, and economic development of Poland by facilitating international partnerships. At PolSV, BioCloner Health representatives presented their original 3D bioprinting technology and initiated early conversations with U.S.-based research institutions and potential business partners.
Another key stop on the itinerary was Stanford University. The BioCloner team visited the Stanford Mussallem Center for Biodesign—one of the world’s leading hubs for medical innovation. The center focuses on developing technologies that improve healthcare quality by combining engineering, medicine, and business. To date, its efforts have led to the creation of more than 50 startups addressing some of the most pressing challenges in modern medicine.
In the following days, the BioCloner Health delegation met with the directors of MBC BioLabs and the Vice President of Product. Discussions centered around potential collaboration opportunities, the development of incubator infrastructure, prototyping, and scaling up production—key areas for advancing technologies within the life sciences sector.
The visit to the United States was not only an opportunity to showcase the BioCloner technology to a wider audience but also a crucial step in building a strong international collaboration network. Meetings with scientific and business leaders, along with visits to prestigious research institutions, confirmed that the solutions developed by BioCloner Health have the potential to become a vital part of the future of regenerative medicine on a global scale.